228 related articles for article (PubMed ID: 33036295)
1. Isavuconazole-Animal Data and Clinical Data.
Pagano L; Cattaneo C; Quattrone M; Oberti M; Mazzitelli M; Trecarichi EM
J Fungi (Basel); 2020 Oct; 6(4):. PubMed ID: 33036295
[TBL] [Abstract][Full Text] [Related]
2. [Current therapeutic options in invasive mycosis and potential therapeutic role of isavuconazole].
Garcia-Vidal C
Rev Iberoam Micol; 2018; 35(4):192-197. PubMed ID: 30455108
[TBL] [Abstract][Full Text] [Related]
3. Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations.
Li J; Nguyen CT; Garcia-Diaz J
J Fungi (Basel); 2015 Oct; 1(3):345-366. PubMed ID: 29376915
[TBL] [Abstract][Full Text] [Related]
4. Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre.
Bowen CD; Tallman GB; Hakki M; Lewis Ⅱ JS
Mycoses; 2019 Aug; 62(8):665-672. PubMed ID: 31050373
[TBL] [Abstract][Full Text] [Related]
5. Role of isavuconazole in the treatment of invasive fungal infections.
Wilson DT; Dimondi VP; Johnson SW; Jones TM; Drew RH
Ther Clin Risk Manag; 2016; 12():1197-206. PubMed ID: 27536124
[TBL] [Abstract][Full Text] [Related]
6. New generation azole antifungals in clinical investigation.
Girmenia C
Expert Opin Investig Drugs; 2009 Sep; 18(9):1279-95. PubMed ID: 19678798
[TBL] [Abstract][Full Text] [Related]
7. Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.
Rybak JM; Marx KR; Nishimoto AT; Rogers PD
Pharmacotherapy; 2015 Nov; 35(11):1037-51. PubMed ID: 26598096
[TBL] [Abstract][Full Text] [Related]
8. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
Ledoux MP; Denis J; Nivoix Y; Herbrecht R
J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442
[TBL] [Abstract][Full Text] [Related]
9. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Sanglard D; Coste AT
Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center.
Van Matre ET; Evans SL; Mueller SW; MacLaren R; Fish DN; Kiser TH
Ann Clin Microbiol Antimicrob; 2019 Mar; 18(1):13. PubMed ID: 30894179
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018.
Messer SA; Carvalhaes CG; Castanheira M; Pfaller MA
Diagn Microbiol Infect Dis; 2020 May; 97(1):115007. PubMed ID: 32081523
[TBL] [Abstract][Full Text] [Related]
12.
Pfaller MA; Rhomberg PR; Wiederhold NP; Gibas C; Sanders C; Fan H; Mele J; Kovanda LL; Castanheira M
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061288
[TBL] [Abstract][Full Text] [Related]
13. Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
Pettit NN; Carver PL
Ann Pharmacother; 2015 Jul; 49(7):825-42. PubMed ID: 25940222
[TBL] [Abstract][Full Text] [Related]
14. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.
Murrell D; Bossaer JB; Carico R; Harirforoosh S; Cluck D
Int J Pharm Pract; 2017 Feb; 25(1):18-30. PubMed ID: 27569742
[TBL] [Abstract][Full Text] [Related]
15. Azole antifungals: 35 years of invasive fungal infection management.
Allen D; Wilson D; Drew R; Perfect J
Expert Rev Anti Infect Ther; 2015 Jun; 13(6):787-98. PubMed ID: 25843556
[TBL] [Abstract][Full Text] [Related]
16. Isavuconazole shortens the QTc interval.
Mellinghoff SC; Bassetti M; Dörfel D; Hagel S; Lehners N; Plis A; Schalk E; Vena A; Cornely OA
Mycoses; 2018 Apr; 61(4):256-260. PubMed ID: 29178247
[TBL] [Abstract][Full Text] [Related]
17. Quantification of Serum Voriconazole, Isavuconazole, and Posaconazole by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS).
Smith A; Dowis J; French D
Curr Protoc Toxicol; 2018 May; 76(1):e47. PubMed ID: 30040225
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.
Livermore J; Hope W
Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):759-65. PubMed ID: 22530880
[TBL] [Abstract][Full Text] [Related]
19. Real-world use-Isavuconazole at a large academic medical center.
Hassouna H; Athans V; Brizendine KD
Mycoses; 2019 Jun; 62(6):534-541. PubMed ID: 30851214
[TBL] [Abstract][Full Text] [Related]
20. Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017).
Desnos-Ollivier M; Bretagne S; Boullié A; Gautier C; Dromer F; Lortholary O;
Clin Microbiol Infect; 2019 May; 25(5):634.e1-634.e4. PubMed ID: 30771532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
